BioSpace News Archive

Obesity

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

The American Diabetes Association’s annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

June 5, 2026

·

8 min read

·

Tristan Manalac

Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.

Sickle cell disease

Fulcrum lays off 85% of staff after dropping asset, leaving 9 employees

After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door.

June 5, 2026

·

2 min read

·

Tristan Manalac

Business meeting idea and planning with strategy as a corporate concept with a mechanical wheel bridge as diverse multiracial businesspeople joining together as a symbol for people diversity and success with 3D render elements.

Career Advice

Surviving (and thriving with) DEI in biotech

Rather than getting hung up on what to call DEI in the workplace, leaders should take three specific actions to help their employees embrace and engage with it. Companies and the patients they serve will benefit.

June 5, 2026

·

3 min read

·

Quin Wills

Opinion

The next FDA commissioner must be a champion for gene therapies

The FDA must provide consistent and predictable regulatory frameworks if the U.S. is to maintain its leadership in gene therapy, one of the most consequential therapeutic fields of our generation.

June 5, 2026

·

4 min read

·

Erik Paulsen

Press Releases

Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors

June 5, 2026

·

3 min read

Press Releases

Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)